Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
COSMO Pharmaceuticals N.V. ( (CH:COPN) ) has shared an announcement.
Cosmo Pharmaceuticals reported that shareholders approved all agenda items at the 2026 Annual General Meeting, with 59.02% of outstanding ordinary shares represented. Investors backed a dividend of EUR 2.10 per share, with the ex-dividend date set for 24 April 2026 and payment scheduled for 11 May 2026, signaling continued confidence in the company’s financial performance and shareholder return policy.
The most recent analyst rating on (CH:COPN) stock is a Hold with a CHF80.00 price target. To see the full list of analyst forecasts on COSMO Pharmaceuticals N.V. stock, see the CH:COPN Stock Forecast page.
More about COSMO Pharmaceuticals N.V.
Cosmo Pharmaceuticals N.V. is a life science company focused on MedTech AI, dermatology, gastrointestinal diseases and contract development and manufacturing services. Founded in 1997 and headquartered in Dublin with operations in the U.S. and Italy, it develops advanced medical solutions used by global pharma and MedTech partners.
Average Trading Volume: 65,214
Technical Sentiment Signal: Buy
Current Market Cap: CHF1.49B
See more data about COPN stock on TipRanks’ Stock Analysis page.